Birmingham, AL, United States of America

Charles O Elson

USPTO Granted Patents = 3 

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2011-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Charles O. Elson

Introduction

Charles O. Elson is a notable inventor based in Birmingham, Alabama, recognized for his contributions to medical research and innovation. With a total of three patents to his name, Elson has made significant strides in the field of immunotherapy and the diagnosis of inflammatory bowel diseases.

Latest Patents

Elson's latest patents include groundbreaking methods and compositions for treating and preventing inflammatory bowel disease. One of his notable inventions focuses on the characterization of the CBir1 antigenic response for the diagnosis and treatment of Crohn's disease. This invention provides methods for diagnosing or predicting susceptibility to Crohn's disease by determining the presence or absence of genetic variants. It also includes methods to diagnose Crohn's disease by assessing anti-Cbir1 reactivity and TLR5 risk variants, as well as the presence of NFKB1 haplotype H3 and ASCA expression.

Career Highlights

Throughout his career, Charles O. Elson has worked with esteemed organizations such as the UAB Research Foundation and Cedars-Sinai Medical Center. His work has significantly impacted the understanding and treatment of inflammatory bowel diseases, showcasing his dedication to advancing medical science.

Collaborations

Elson has collaborated with notable colleagues, including Yingzi Cong and Kent D. Taylor, further enhancing the scope and impact of his research.

Conclusion

Charles O. Elson's innovative work in immunotherapy and disease diagnosis exemplifies the vital role of inventors in advancing medical research. His contributions continue to influence the field and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…